Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States

References

• Bixler EO, Kales A, Soldatos CR, et al. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257–62
   PubMed Web of Science ®Google Scholar
• Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479–84
   PubMed Web of Science ®Google Scholar
• Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population. J Gen Intern Med 1995;10:25–32
   PubMed Web of Science ®Google Scholar
• Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985;42:225–32
   Google Scholar
• Ustun T, Privett M, Lecrubier Y, et al. Form, frequency and burden of sleep problems in general health care: a report from the WHO Collaborative Study on Psychological Problems in General Health Care. European Psychiatry 1996;11\(Suppl 1): 5–10s
   Google Scholar
• Terzano M.G, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Safety 2003;26:261–82
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002;6:97–111
   PubMed Web of Science ®Google Scholar
• Perlis ML, Smith LJ, Lyness JM, et al. Insomnia as a risk factor for onset of depression in the elderly. Behav Sleep Med 2006;4:104–13
   PubMedGoogle Scholar
• Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manage Care 2006;12(Suppl 8):S214–20
   PubMed Web of Science ®Google Scholar
• Gooneratne NS, Gehrman PR, Nkwuo JE, et al. Consequences of comorbid insomnia symptoms and sleep-related breathing disorder in elderly subjects. Arch Intern Med 2006;166: 1732–8
   PubMed Web of Science ®Google Scholar
• NIH Statement Regarding the Treatment of Insomnia. Manifestations and management of chronic insomnia in adults. Sleep 2005;28:1049–57
   Google Scholar
• Hatoum HT, Kong SX, Kania CM, et al. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. Pharmacoeconomics 1998;14:629–37
   Google Scholar
• Leger D, Guilleminault C, Bader G, et al. Medical and socio-professional impact of insomnia. Sleep 2002;25:625–9
   PubMed Web of Science ®Google Scholar
• Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354–8
   PubMed Web of Science ®Google Scholar
• Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. An overview. Pharmacoeconomics 1996;10(Suppl 1):1–14
   PubMedGoogle Scholar
• Stoller MK. Economic effects of insomnia. Clin Ther 1994;16:873–97
   PubMed Web of Science ®Google Scholar
• Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(Suppl 2):S386–93
   PubMed Web of Science ®Google Scholar
• Leger D, Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysomatic condition. Curr Med Res Opin 2005;21:1785–92
   PubMed Web of Science ®Google Scholar
• Hohagen F, Rink K, Kappler C, et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 1993;242:329–36
   PubMed Web of Science ®Google Scholar
• IMS Health. Commonly requested therapeutic class and product information (update February 2006). Available at: www.imshealth.com/ims/portal/front/articleC/0,2777,6599_18731_77056778,00.html [Last accessed 28 March 2007]
   Google Scholar
• Morin AK. Strategies for treating chronic insomnia. Am J Manag Care 2006;12:S230–45
   PubMed Web of Science ®Google Scholar
• Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006;18:49–56
   PubMedGoogle Scholar
• Fullerton DS. The economic impact of insomnia in managed care: a clearer picture emerges. Am J Manag Care 2006;12:S246–52
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S. The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care 2006;12:S221–9
   PubMed Web of Science ®Google Scholar
• Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: upate of the recent evidence (1998–2004). Sleep 266629:1398–414
   Google Scholar
• Botteman, Ozminkowski RJ, Wang S, et al. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs 2007;21: 319–34
   PubMed Web of Science ®Google Scholar
• Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs. zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006;295:2851–8
   Google Scholar
• Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology: Clinical and Experimental 1998;13:191–8
   Web of Science ®Google Scholar
• Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:249–60
   PubMed Web of Science ®Google Scholar
• Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60(Suppl 17):28–31
   PubMed Web of Science ®Google Scholar
• Morlock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of the National Ambulatory Medical Survey data, 1997–2002. Clin Ther 2006;28: 1044–53
   Google Scholar
• Roehrs T, Roth T. ‘Hypnotic’ prescription patterns in a large managed-care population. Sleep Med 2004;5:463–6
   PubMed Web of Science ®Google Scholar
• Roth T, Soubrane C, Titeux L, et al. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 2006;7:397–406
   PubMed Web of Science ®Google Scholar
• Herrmann WM, Kubicki ST, Boden S, et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic ‘learned’ insomnia: psychometric and polysomnographic evaluation. J Int Med Res 1993;6: 306–22
   Google Scholar
• Monti JM, Monti D, Estevez F, et al. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996;11:255–63
   PubMed Web of Science ®Google Scholar
• Ware JC, Walsh JK, Scharf MB, et al. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharmacol 1997;20:116–25
   PubMed Web of Science ®Google Scholar
• Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192–9
   PubMed Web of Science ®Google Scholar
• Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979–91
   PubMed Web of Science ®Google Scholar
• The Neurocrine Company. Phase III Chronic Insomnia (Indiplon-IR). Available at: www.neurocrine.com/pdf/CurrentSlidePresentation.pdf (slide 31). [Last accessed 28 March 2007]
   Google Scholar
• Zammit G, Roth T, Erman M, et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 2005;28:A228–9
   Web of Science ®Google Scholar
• Roth T, Zammit G, Jochelson P, et al. Efficacy and safety of indiplon-IR in adults with chronic insomnia characterized by prolonged nighttime awakenings with difficulty returning to sleep. American Psychiatric Association 2005 Annual Meeting; May 21–26, 2005; Atlanta, Georgia. Sleep 2005:Abstract NR683
   Google Scholar
• Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17–24
   PubMed Web of Science ®Google Scholar
• Walsh JK, Vogel GW, Scharf M, et al. A five week, polysomno-graphic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 2000;1:41–9
   PubMed Web of Science ®Google Scholar
• Culpepper L. Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin 2006;22:1257–68
   PubMed Web of Science ®Google Scholar
• Greene WH. Econometric Analysis. Upper Saddle River, N.J: Prentice Hall, 2000
   Google Scholar
• Wooldridge JM. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press, 2002
   Google Scholar
• Micromedex® Healthcare Series – Red Book Ready Price®. Greenwood Village, CO: Thompson Micromedex, updated periodically [Last accessed 31 May 2006]
   Google Scholar
• Annual Estimates of the Population by Selected Age Groups and Sex for the United States: April 1, 2000 to July 1, 2004. United States Census Bureau. Available at: www.census.gov/popest/national/asrh/NC-EST2004-sa.html. [Last accessed 22 August 2006]
   Google Scholar
• 2005 Sleep in America Poll. National Sleep Foundation, 2005. Washington DC. Available at: www.sleepfoundation.org [Last accessed 15, July 2006]
   Google Scholar
• Ancoli-Israel S, Roth T. Characteristics of insomnia in the United Status: results of the 1991 National Sleep Foundation Survey. Sleep 1999; 22\(Suppl 2):S347–53
   Google Scholar
• Doghramji K. The epidemiology and diagnosis of insomnia. Am J Manag Care 2006;12:S214–20
   PubMed Web of Science ®Google Scholar
• Walsh JK. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004;65(Suppl 8):13–19
   PubMed Web of Science ®Google Scholar